AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05243810 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EPC Silver Wound Gel
Description: Re-application of EPC-123 will occur within 48 hours of the initial application. Secondary dressings will be selected at the discretion of the clinician or home care provider, based upon best practice guidelines for moisture management and will consist of a selection between the following secondary dressings: Mesorb® (Molnyke), Gauze, Cling (self-adherent gauze), or MediporeTM (3M). Application of EPC-123 will be executed at the Lawson Health Research Institute every second visit, where interim applications will be facilitated by home care. To support home care applications, a study kit will be provided to home care professionals inclusive of the EPC Silver Wound Gel, secondary dressings required, and instructions for removal/re-application.
Study NCT05037409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06823859
Description: low dose or high dose intravenous infusion
Study NCT05037409 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous infusion
Study NCT06111131 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Enteroscopy
Description: A procedure that uses a specially equipped endoscope to examine the small intestine lining. An enteroscopy uses an endoscope, a tube with a light and camera on the end and the endoscope, in the case of this study, is equipped with a single balloon overtube to advance the scope deeper into the small intestine, to reach the middle third of the small bowel.
Study NCT05471973 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Outreach Visits
Description: An outreach visit consulting group from the coordinating center and trial leadership will provide external guidance on reviewing data, defining barriers, and implementing interventions
Study NCT05471973 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Multifaceted Intervention
Description: These interventions are not limited to targeted engagement with non-extractors, electronic health record (EHR) decision support, creation of OR block time, use of opinion leaders, and development of clinical pathways. In addition, once patients are identified and referred to extraction centers, clinical pathways are needed to provide prompt care without clinical delay
Study NCT05471973 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Measurement and Feedback
Description: The coordinating center will provide ongoing feedback related to the site's data. This will include time to diagnosis, treatment, and outcomes related to the device infection.
Study NCT06127420 — intervention group
Intervention type: OTHER
Intervention: coronary physiological indices
Description: Resting distal coronary to aortic pressure ratio, Fractional flow reserve, Resting full-cycle ratio, Coronary Flow Reserve, Microvascular resistance
Study NCT05407545 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Current prosthesis
Description: A unilateral transfemoral amputee will conduct experiments with the current prosthesis
Study NCT05407545 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Prosthesis (PowerKnee)
Description: A unilateral transfemoral amputee will conduct experiments with the Power Knee. The PowerKnee is an active prosthesis developed by Össur.
Study NCT06280859 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hoosier Sport
Description: Hoosier Sport is a sport-based youth development intervention. The intervention targets physical activity levels, exercise and nutrition knowledge, and leadership skills. The intervention is delivered in person twice a week (Tue/Thu) during PE class. Each class lasts 45-minutes, and covers sport skills, and then a brief lecture and activity on exercise/nutrition/leadership skills. Additionally, once a week Hoosier Sport is delivered virtually (via Zoom) during home room for 20-minutes. This involves activities to allow the students to be active during the school-day.
Study NCT06583174 — intervention group
Intervention type: BEHAVIORAL
Intervention: Breastfeeding Attitudes
Description: Relationship between Breastfeeding Attitudes and Nutrition Knowledge Levels
Study NCT05961956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVDX3
Description: NVDX3 is implanted during a single surgical intervention.
Study NCT05539950 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary rehabilitation
Description: Cardiopulmonary rehabilitation helps patients maximize functional potential due to progressive deconditioning or acute decompensation following an acute medical event. This intervention is medically supervised and individualized according to their results of the cardiopulmonary Exercise Testing (CPET).
Study NCT05539950 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health education
Description: Individualized exercise prescription will be given according to their results of the cardiopulmonary Exercise Testing (CPET). Recommendations for lifestyle modification will also be given.
Study NCT05539950 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health education
Description: Individualized exercise prescription will be given according to their results of the cardiopulmonary Exercise Testing (CPET). Recommendations for lifestyle modification will also be given.
Study NCT05123209 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IM83 CAR-T cells
Description: 3×10\^9 CAR-T cells
Study NCT05123209 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: The second-line treatment of liver cancer
Description: approved by NMPA
Study NCT04190550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV
Study NCT04190550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin Hydrochloride
Description: Given IV
Study NCT04190550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navtemadlin
Description: Given PO
Study NCT05512988 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UC-MSC
Description: Usage: The stem cell preparation in this study is used intravenously in the elbow.~Dose: The dose of stem cell injection in this clinical study is set at 1×10\^6/Kg/time per injection, and the injection frequency is 2 weeks/time.~Duration: 2 injections per trial group for the entire duration of the course, with a total dose of 2×10\^6/Kg/person.
Study NCT05512988 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution
Description: Usage: The saline solution in this study is used intravenously in the elbow.~Dose: The dose of saline solution in this clinical study is set at 250ml/time per injection, and the injection frequency is 2 weeks/time.~Duration: 2 injections per person for the entire duration of the course
Study NCT04546178 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged exposure (PE)+ therapy
Description: The intervention will be adapted prolonged exposure therapy, called PE+ therapy. Participants will receive 15 weekly 90-minute sessions of PE+; these appointments will be divided into five sets of three sessions each: 1) psychoeducation about AEs, SM, and the interplay of both with psychosis; 2) emotion regulation strategies; 3) imaginal exposures, 4) in vivo exposures, and 5) review of treatment and planning for termination and maintenance.
Study NCT04546178 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as usual (TAU)
Description: The intervention will be antipsychotics prescribed by clinicians working within the Nova Scotia Early Psychosis Program (NSEPP) as well as case management supplied by their primary nurse. Program participants will have access to educational programs about psychosis, skills/vocational training, as well as familial education and support.
Study NCT04546178 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual (TAU)
Description: The intervention will be antipsychotics prescribed by clinicians working within the Nova Scotia Early Psychosis Program (NSEPP) as well as case management supplied by their primary nurse. Program participants will have access to educational programs about psychosis, skills/vocational training, as well as familial education and support.
Study NCT06464055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose Escalation
Description: GQ1010
Study NCT06464055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose Expansion1
Description: GQ1010 dose1
Study NCT06460103 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placement of a Straumann® Bone Level Tapered implant SLActive® (hydrophilic surface)
Description: Immediately after tooth extraction, patients will receive a Straumann® Bone Level Tapered SLActive® mini-implant at the ideal prosthetic position of the final implant, and bone augmentation using bone graft maxgraft®  and dental membrane collprotect®membrane.~The mini-implant will be removed as a core trephine biopsy; the resulting osteotomies will be fine-prepared, and the final permanent implant will be placed after a healing period of 3 weeks post-augmentation.
Study NCT06460103 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Placement of a Straumann® Bone Level Tapered implant SLA® (hydrophobic surface)
Description: Immediately after tooth extraction, patients will receive a Straumann® Bone Level Tapered SLA® mini-implant at the ideal prosthetic position of the final implant, and bone augmentation using bone graft maxgraft®  and dental membrane collprotect®membrane.~The mini-implant will be removed as a core trephine biopsy; the resulting osteotomies will be fine-prepared, and the final permanent implant will be placed after a healing period of 3 weeks post-augmentation.
Study NCT06464055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose Expansion2
Description: Drug: GQ1010 dose2
Study NCT05513222 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: flipped autograft
Description: Thick lingual flap was de-epithelized and partially dissected to increase its length then flipped and sutured to the buccal flap to obtain primary closure
Study NCT06464055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: phase II
Description: Drug: GQ1010 RP2D
Study NCT05549843 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual therapy
Description: Each session will last approximately 50-60 minutes, with 1 physiotherapy session per week over a period of 3 weeks. Each session is made up of 10 steps, of which 9 correspond to manual interventions commonly used in the field of manual therapy.
Study NCT05605418 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHESS intervention
Description: The multi-faceted CHESS intervention includes: (1) home blood pressure monitoring (HBPM) for patients, and the data will be uploaded to central electronic health records (EHR) automatically; (2) a Smart Reminder and Alert System (SRAS) to send educational messages and reminders to support patients on HBPM, improve blood pressure medication adherence and lifestyle modification; (3) a decision support system (DSS) to provide physicians with antihypertensive medications prescriptions and referral recommendations; (4) regular quality assessment reports will be provided to health care providers automatically to improve the quality of hypertension management at PHC level.
Study NCT06209580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMT-253 for injection
Description: Administered intravenously
Study NCT05517707 — intervention group
Intervention type: DEVICE
Intervention: Nasogastric Tube
Description: Temperature and impedance data will be collected from sensors embedded within the feeding tube wall.
Study NCT04889560 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental group
Description: Home-based version of a computerized cognitive training (CoRe)
Study NCT04889560 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: Computerized cognitive training (CoRe)
Study NCT06198439 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: Magstim Rapid2 Therapy System
Study NCT05477823 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External beam radiation therapy
Description: Standard of care EBRT
Study NCT05477823 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Prostate brachytherapy boost
Description: Standard of care BTX
Study NCT05477823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy
Description: Standard of care ADT
Study NCT05477823 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Positron emission tomography (PET)/magnetic resonance imaging (MRI)
Description: Pelvic PET scanning with tracer will take approximately 45 minutes. This will be followed by the injection of a contrast agent followed by whole body PET/MRI scanning which will take approximately 30 minutes.
Study NCT05367453 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tropical juice with probiotics (B.coagulans)
Description: Once a day during all the intervention phase, volunteers with lactose intolerance should allow the spore-forming ability of B. coagulans in order to digest lactase from dairy products through regular consumption of Tropical juice with probiotics (B.coagulans)
Study NCT05367453 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: a Tropical juice with no probiotics
Description: Once a day during all the intervention phase, volunteers with lactose intolerance should consume a Tropical juice with no probiotics
Study NCT05367453 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: lactase tablet
Description: lactase tablet
Study NCT05367453 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo tablet (cornstarch)
Description: placebo tablet (cornstarch)
Study NCT05257538 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FMT
Description: Fecal microbiota transfer from a healthy and tested volunteer
Study NCT05257538 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo enema
Description: colored water enema
Study NCT04654689 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Liposomed polyphenols resveratrol and curcumin
Description: Combination of resveratrol (75mg) and curcumin (200mg) liposomed
Study NCT04654689 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for liposomed resveratrol and curcumin
Description: Water with sucrose replacing the liposomed polyphenols
Study NCT04654689 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Isocaloric Diet
Description: 40% carbohydrates, 40% lipids and 20% proteins
Study NCT04654689 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Isocaloric Diet
Description: 40% carbohydrates, 40% lipids and 20% proteins
Study NCT04654689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G04CB02
Description: G04CB02, in a single daily dose for 4 months
Study NCT04654689 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo microcrystalline methylcellulose
Description: Placebo replacing G04CB02
Study NCT05558410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-548
Description: Tablets for oral administration.
Study NCT05558410 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HB/APAP
Description: Capsules for oral administration.
Study NCT05558410 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (matched to VX-548)
Description: Placebo matched to VX-548 for oral administration.
Study NCT05558410 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (matched to VX-548)
Description: Placebo matched to VX-548 for oral administration.
Study NCT05558410 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (matched to HB/APAP)
Description: Placebo matched to HB/APAP for oral administration.
Study NCT05558410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (matched to HB/APAP)
Description: Placebo matched to HB/APAP for oral administration.
Study NCT05809453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cocaine
Description: Cocaine will be administered intranasally prior to entering the warm environmental conditions and performing 60 minutes of exercise.
Study NCT05809453 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lidocaine
Description: Lidocaine will be administered intranasally prior to entering the warm environmental conditions and performing 60 minutes of exercise.
Study NCT05550025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: camrelizumab& apatinib
Description: TACE（transcatheter arterial chemoembolization） combined with Apatinib and Camrelizumab Camrelizumab 200mg every 3 weeks. Taking Apatinib-Mesylate Tablets (250 mg/tablet) orally after meals, once a day, for continuous medication.~The cumulative maximum drug use period is up to 1 years. The patient is concurrent on medication until the treatment discontinuation criteria specified in the protocol appear.
Study NCT06573788 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet + wearble device multimodal prehabilitation
Description: Use the Prehabilitation Learning Platform to learn what to do and follow along with the videos for follow up exercises
Study NCT06573788 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: traditional multimodal prehabilitation
Description: The researchers used a prehabilitation manual to explain to subjects what they needed to do, and the patients went home and practiced on their own, recording the exercises daily
Study NCT05565612 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Normodigest Classic
Description: Symbiotic composed of 15 probiotic strains and fructooligosaccharides as prebiotic
Study NCT05565612 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Compound based on maltodextrin and other excipients
Study NCT05068765 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Communication skills psychoeducation
Description: Intervention explanations are explained in the groups section.
Study NCT05068765 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: General psychoeducation
Description: İntervention descriptions are explained in the intervention groups section.
Study NCT05286918 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The intervention (CRP-guided) group
Description: The attending doctor will use the CRP level to inform their decision to continue antibiotics around 3 hours from blood taking. These doctors will be provided pre-study training on CRP interpretation.~Every day from randomization, serum CRP testing will be encouraged to take. Once CRP has declined to \<5mg/dL and the patient has remained afebrile for past 48 hours, antibiotic treatment will be reviewed for discontinuation. Otherwise, antibiotic treatment will be continued. A switch on the administration route, or a change of antibiotics due to adverse effect, allergy, or suggestion from culture result, is permitted according to in-patient physician's decisions. CRP will continue to be monitored daily upon discharge from that hospital (up to 28 days).
Study NCT06132100 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: digitalized incentive spirometry
Description: digitalized incentive spirometry
Study NCT06132100 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: traditional incentive spirometry
Description: traditional incentive spirometry
Study NCT06300541 — intervention group
Intervention type: PROCEDURE
Intervention: Colectomy
Description: Observational study.
Study NCT05481112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended-Release Buprenorphine Injection
Description: Extended-release buprenorphine (XR-B, Sublocade) is manufactured by Indivior. XR-B consists of a depot injectable formulation in polymeric solution to the abdomen and releases buprenorphine over 28-days (4-weeks) by diffusion as the polymer biodegrades.
Study NCT05693922 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Delta-beta cross-frequency transcranial alternating current stimulation via the NeuroConn DC-STIMULATOR MC
Description: Delta-beta stimulation will be delivered via the NeuroConn DC-STIMULATOR MC, an investigational electrical non-invasive brain stimulation device that is being used for foundational neuroscience and translational research.
Study NCT05693922 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Single-session behavioral activation
Description: Participants will take part in a single-session behavioral activation (BA) intervention. This intervention was adapted from standard BA protocols for the treatment of depression to be completed in a single, 90-minute session. This intervention will have 4 main components based on prior protocols:~* Treatment overview and rationale~* Tracking of daily activities~* Exploration of values~* Planning/scheduling activities
Study NCT05282810 — intervention group
Intervention type: OTHER
Intervention: tympanoplasty
Description: use of cartilage versus tempotalis fascia in tympanoplasty for recuurent perforation
Study NCT04649892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: Patients will receive daily doses of Naltrexone, starting at 50mg and increasing 25mg per week until reaching 200mg or the maximum tolerated by the patient
Study NCT04649892 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive daily doses placebo matching tablets for the 12 weeks of the study. Throughout this period, possible adverse effects will be monitored weekly.
Study NCT04649892 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducational
Description: Participants will also attend to 4 sessions of psychoeducational intervention in weeks 2, 4, 6, and 8